Lupin Ltd — Regulatory Filings 2021

Sep 28, 2021

September 28. 2021

" BSE Limited Department of Corporate Services. P. J. Towers. Dalal Street. MUMBAI - 400 001 .

National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex. Bandra (East). Mumbai - 400 051.

Sub: Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sir/Madam,

Enclosed is a Press Release as regards launch of Droxidopa Capsules, 100 mg, 200 mg. and 300 mg, having received an approval from the U.S. FDA.

This may kind ly be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Thanking you,

Yours faithfully, For LUPIN LIMITED

R. V. SATAM COMPANY SECRETARY (ACS - 11973)

Encl.: a/ a

LUPIN LIMITED

Registered Office: 3'' Floor, Kalpataru Inspire, Off W. E. Highway. Santacruz (East). Mumbai - 400 055 India. Tel : (91 -22) 6640 2323. Corporate Identity Number: L241OOMH1983PLC029442 www.lupin.com

Lupin Launches Droxidopa Capsules in the United States

Mumbai, Baltimore, September 28, 2021: Global pharma major Lupin Limited (Lupin) today announced the launch of Droxidopa Capsules, 100 mg, 200 mg, and 300 mg, having received an approval from the United States Food and Drug Administration (US FDA). Th e product is manufactured at Lupin's facility in Nagpur, India.

Droxidopa Capsules, 100 mg, 200 mg, and 300 mg is a generic equivalent of Northera® Capsules, 100 mg, 200 mg, and 300 mg, of Lundbeck NA Ltd., indicated for the treatment of orthostatic dizziness, lightheadedness, or the "feeling that you are about to black out" in adult patients with symptomatic neurogen ic orthostatic hypotension (nOH) caused by primary autonomic failure (Parkinson's disease, multiple system atrophy, and pure autonomic failure), dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy.

Droxidopa Capsules (RLD: Northera®) had estimated annual sales of USD 294 million in the U.S. {IQVIA MAT July 2021).

About Lupin

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APls in over 100 markets in the U.S., India, South Africa and across Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions.

The Company enjoys leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS) and women's health areas. Lupin is the third largest pharmaceutical company in the U.S. by prescriptions. The company invested 9.6% of its revenue on research and development in FY21.

Lupin has 15 manufacturing sites, 7 research centres, more than 20,000 professionals working globally, and has been consistently recognized as a 'Great Place to Work' in the Biotechnology & Pharmaceuticals sector.

Please visit www.lupin.com for more information.

Follow us on Twitter: https://twitter.com/LupinGlobal I Linkedln: https://www.linkedin.com/company/lupin Facebook: http://www.facebook.com/LupinWorld/

For further information or queries please contact -

Shweta Munjal Vice President & Global Head - Corporate Communications Email: shwetamunjal@lupin.com

BSE:500257 NSE: LUPIN REUTERS: LUPIN.BO BLOOMBERG: LPCIN

•sate Harbor Statement

Northera~ is a registered trademark of Lundbeck NA Ltd.